Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Venetoclax

Nausea and cytopenia following off-label use: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kent A, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplantation 58 : 849-854, No. 8, Aug 2023. Available from: URL: https://www.nature.com/bmt/ Kent A, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplantation 58 : 849-854, No. 8, Aug 2023. Available from: URL: https://​www.​nature.​com/​bmt/​
Metadaten
Titel
Venetoclax
Nausea and cytopenia following off-label use: 2 case reports
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48933-3

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Isotretinoin

Case report

Levofloxacin

Case report

Treprostinil

Case report

Linezolid

Case report

Amoxicillin